Cetuximab in non-small-cell lung cancer

Expert Review of Anticancer Therapy

Volumn 12, Issue 2, 2012, Pages 163-175

  Carillio, Guido ^a   Montanino, Agnese ^b   Costanzo, Raffaele ^b   Sandomenico, Claudia ^b   Piccirillo, Maria Carmela ^b   Di Maio, Massimo ^b   Daniele, Gennaro ^b   Giordano, Pasqualina ^b   Bryce, Jane ^b   Normanno, Nicola ^b,c   Rocco, Gaetano ^b   Perrone, Francesco ^b,c   Morabito, Alessandro ^b  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

cetuximab; clinical trials; EGFR; NSCLC

Indexed keywords

AFATINIB; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX;

ANEMIA; ASEPTIC MENINGITIS; ASTHENIA; BACTERIAL ENDOCARDITIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA; CHEMORADIOTHERAPY; CHILL; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPHAGIA; DYSPNEA; EPIGLOTTITIS; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GENE MUTATION; HEAD AND NECK CANCER; HEADACHE; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; HYPOMAGNESEMIA; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LOADING DRUG DOSE; LUNG CARCINOGENESIS; LUNG EMBOLISM; LUNG SMALL CELL CANCER; MAINTENANCE DRUG DOSE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PATIENT COMPLIANCE; PNEUMONIA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE; RASH; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SEPSIS; SINGLE DRUG DOSE; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; EPIDERMAL GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84856844739     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.178     Document Type: Review

References (44)

1. Ciardiello F, Tortora G. EGFR Antagonist in cancer treatment. N. Engl. J. Med. 358, 1160-1174 (2008).
2. Mendelsohn J, Baselga J. Status of epidermal growth receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21, 2787-2799 (2003). (Pubitemid 46606324)
3. Voon PJ, Cho BC, Yeo WL, Soo RA. The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer. J. Thorac. Dis. 3, 144-153 (2010).
4. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18(4), 904-914 (2000). (Pubitemid 30106623)
5. Fracasso PM, Burris H III, Arquette MA et al. A Phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: Pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 13(3), 986-993 (2007). (Pubitemid 46340377)
6. Ramalingam S, Forster J, Naret C et al. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): A Phase I study. J. Thorac. Oncol. 3(3), 258-264 (2008). (Pubitemid 351654325)
7. Harding J, Burtness B. Cetuximab: An epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today 41(2), 107-127 (2005). (Pubitemid 40461533)
8. Guarino MJ, Schneider CJ, Hosford MA et al. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: A Phase I study in patients with advanced solid malignancies. Oncologist 14(2), 119-124 (2009).
9. Ho C, Sangha R, Beckett L et al. Escalating weekly doses of cetuximab and correlation with skin toxicity: A Phase I study. Invest. New Drug 29, 680-687 (2011).
10. Hanna N, Lilenbaum R, Ansari R et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J. Clin. Oncol. 24(33), 5253-5258 (2006). (Pubitemid 46631370)
11. Thienelt CD, Bunn PA Jr, Hanna N et al. Multicenter Phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J. Clin. Oncol. 23(34), 8786-8793 (2005). (Pubitemid 46211524)
12. Herbst RS, Kelly K, Chansky K et al. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J. Clin. Oncol. 28(31), 4747-4754 (2010).
13. Belani CP, Schreeder MT, Steis RG et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: A multicenter Phase 2 study. Cancer 113(9), 2512-2517 (2008).
14. Rosell R, Robinet G, Szczesna A et al. Randomized Phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol. 19(2), 362-369 (2008). . Randomized Phase II trial suggesting a promising role for the addition of cetuximab to platinum-based first-line chemotherapy in advanced non-small-cell lung cancer (NSCLC). (Pubitemid 351201721)
15. Robert F, Blumenschein G, Herbst RS et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J. Clin. Oncol. 23(36), 9089-9096 (2005).
16. Butts CA, Bodkin D, Middleman EL et al. Randomized Phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J. Clin. Oncol. 25(36), 5777-5784 (2007).
17. Gridelli C, Morabito A, Gebbia V et al. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized Phase II trials. Lung Cancer 67(1), 86-92 (2010).
18. Lilenbaum R, Wang X, Gu L, Kirshner J, Lerro K, Vokes E. Randomized Phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J. Clin. Oncol. 27(27), 4487-4491 (2009).
19. Groen HJ, Horn L, Smit EF et al. Activity and tolerability of combined EGFR targeting with afatinib (BIBW 2992) and cetuximab in T790M+ NSCLC patients. Presented at: 14th World Conference on Lung Cancer. Amsterdam, The Netherlands, 3-7 July 2011.
20. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised Phase III trial. Lancet 373(9674), 1525-1531 (2009). .. Randomized Phase III trial that documents a significant prolongation of overall survival with the addition of cetuximab to first-line chemotherapy for advanced NSCLC.
21. Gatzemeier U, von Pawel J, Vynnychenko I et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX Phase 3 study. Lancet Oncol. 12(1), 30-37 (2011). . Subgroup analysis of the FLEX trial, suggesting a significant association between the early occurrence of skin rash and treatment efficacy.
22. O'Byrne KJ, Gatzemeier U, Bondarenko I et al. Molecular biomarkers in non-small-cell lung cancer: A retrospective analysis of data from the Phase 3 FLEX study. Lancet Oncol. 12(8), 795-805 (2011).
23. Pirker R, Paz Ares L, Eberhardt WEE et al. Epidermal growth factor receptor (EGFR) expression as a predictor of survival for first-line chemotherapy plus cetuximab in FLEX study patients with advanced non-small cell lung cancer (NSCLC). Presented at: 14th World Conference on Lung Cancer. Amsterdam, The Netherlands, 3-7 July 2011. .. Subgroup analysis of the FLEX trial, suggesting a significant association between intensive EGF receptor staining by immunohystochemistry and the efficacy of cetuximab.
24. Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter Phase III trial BMS099. J. Clin. Oncol. 28(6), 911-917 (2010). . Another randomized Phase III trial testing the addition of cetuximab to first-line chemotherapy for advanced NSCLC.
25. Khambata-Ford S, Harbison CT, Hart LL et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a Phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 28(6), 918-927 (2010).
26. Pujol J, Lyncy TJ, Rosell R et al. A meta-analysis of four randomized Phase II/III trials adding cetuximab to platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC). Eur. J Cancer 2(Suppl. 7), 508 (2009).
27. Blumenschein GR Jr, Paulus R, Curran WJ et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIa/b non-small-cell lung cancer: RTOG 0324. J. Clin. Oncol. 29(17), 2312-2318 (2011).
28. Govindan R, Bogart J, Stinchcombe T et al. Randomized Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B Trial 30407. J. Clin. Oncol. 29(23), 3120-3125 (2011).
29. Hallqvist A, Wagenius G, Rylander H et al. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: Satellite - a Phase II study from the Swedish Lung Cancer Study Group. Lung Cancer 71(2), 166-172 (2011).
30. Jensen AD, Münter MW, Bischoff HG et al. Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: The NEAR trial. Cancer 117(13), 2986-2994 (2011).
31. Jatoi A, Schild SE, Foster N et al. A Phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422). Ann. Oncol. 21(10), 2040-2044 (2010).
32. Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27(5), 672-680 (2009).
33. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360(6), 563-572 (2009).
34. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin. Lung Cancer 8(Suppl. 1), S7-S14 (2006).
35. Perrone F. Cetuximab in NSCLC: Another trial needed. Lancet Oncol. 12(1), 3-4 (2011).
36. Morabito A, Piccirillo MC, Monaco K, Falasconi F, Normanno N, Perrone F. Methodological Issues of Clinical Research with EGFR Inhibitors. Current Cancer Therapy Reviews 3(4), 1-11 (2007).
37. Morabito A, Di Maio M, De Maio E et al. Methodology of clinical trials with new molecular-targeted agents: Where do we stand? Ann. Oncol. 17(Suppl. 7), vii128-vii131 (2006). (Pubitemid 43985193)
38. Betensky RA, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J. Clin. Oncol. 20(10), 2495-2499 (2002). (Pubitemid 34525735)
39. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann. Oncol. 16(9), 1425-1433 (2005). (Pubitemid 41222414)
40. Perez-Soler R, Delord JP, Halpern A et al. HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10, 345-356 (2005). (Pubitemid 40647253)
41. Boucher KW, Davidson K, Mirakhur B et al. Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J. Am. Acad. Dermatol. 47, 632-633 (2002).
42. Lacouture ME, Anadkat MJ Bensadoun R et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support. Care Cancer 19, 1079-1095 (2011).
43. Lacouture ME, Maitland ML, Segaert S et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC sin toxicity study group. Support. Care Cancer 18, 509-522 (2010).
44. Atherton PJ, Burger KN, Loprinzi CL et al. Using the Skindex-16 and Common Terminology Criteria for adverse events: Results of a pooled analysis (NO993). Support. Care Cancer doi:10.1007/s00520-011-1266-x (2011) (Epub ahead of print).